Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 2/20 | 0.74 |
| ▸ | POLB | P06746 | 2/20 | 0.74 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.74 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.74 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.69 |
| ▸ | ATM | Q13315 | 1/20 | 0.67 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.65 |
| ▸ | LMNA | P02545 | 2/20 | 0.65 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.65 |
| ▸ | HPGD | P15428 | 1/20 | 0.65 |
| ▸ | PTBP1 | P26599 | 1/20 | 0.65 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.65 |
| ▸ | NPC1 | O15118 | 1/20 | 0.65 |
| ▸ | MEN1 | O00255 | 2/20 | 0.64 |
| ▸ | GAA | P10253 | 2/20 | 0.64 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.64 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.63 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.61 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.61 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.61 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2776267 | 0.97 | TSHR (0.70) | TSHRPOLBALOX15MAPK1L3MBTL1 | |
| SCHEMBL2923610 | 0.88 | ATM (0.64) | TSHRPOLBALOX15MAPK1L3MBTL1 | |
| SCHEMBL31526266 | 0.87 | PTGS1 (0.72) | TSHRPOLBALOX15MAPK1L3MBTL1 | |
| SCHEMBL1776304 | 0.87 | MAPK1 (0.57) | TSHRPOLBALOX15MAPK1L3MBTL1 | |
| SCHEMBL14711335 | 0.87 | POLB (0.57) | TSHRPOLBALOX15MAPK1L3MBTL1 | |
| SCHEMBL3294932 | 0.87 | POLB (0.57) | TSHRPOLBALOX15MAPK1L3MBTL1 | |
| SCHEMBL2923341 | 0.86 | SMN1; SMN2 (0.62) | TSHRPOLBALOX15MAPK1L3MBTL1 | |
| SCHEMBL4088587 | 0.86 | ALDH1A1 (0.59) | TSHRPOLBALOX15MAPK1L3MBTL1 | |
| SCHEMBL14711337 | 0.86 | POLB (0.56) | TSHRPOLBALOX15MAPK1L3MBTL1 | |
| SCHEMBL13674 | 0.86 | CACNA1F (0.62) | TSHRPOLBALOX15MAPK1L3MBTL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 28 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2668183-B1 | IL17 AND IFN-GAMMA INHIBITION FOR THE TREATMENT OF AUTOIMMUNE INFLAMMATION | 4SC DISCOVERY GMBH (DE) | 2017-11-01 | — | — | EP | disclosed |
| EP-2668182-B1 | IL17 AND IFN-GAMMA INHIBITION FOR THE TREATMENT OF AUTOIMMUNE INFLAMMATION | 4SC DISCOVERY GMBH (DE) | 2017-11-01 | — | — | EP | disclosed |
| EP-2227475-B1 | ISOXAZOLOPYRIDINE DERIVATIVES FOR USE IN THE TREATMENT OF HIF-MEDIATED CONDITIONS | FIBROGEN INC (US) | 2014-02-19 | — | — | EP | disclosed |
| EP-2668183-A1 | IL17 AND IFN-GAMMA INHIBITION FOR THE TREATMENT OF AUTOIMMUNE INFLAMMATION | 4SC Discovery GmbH (DE) | 2013-12-04 | — | — | EP | disclosed |
| EP-2668182-A1 | IL17 AND IFN-GAMMA INHIBITION FOR THE TREATMENT OF AUTOIMMUNE INFLAMMATION | 4SC Discovery GmbH (DE) | 2013-12-04 | — | — | EP | disclosed |
| US-8592456-B2 | IL17 and IFN-gamma inhibition for the treatment of autoimmune inflammation | 4SC DISCOVERY GMBH (DE) | 2013-11-26 | — | — | US | disclosed |
| US-8354436-B2 | IL17 and IFN-gamma inhibition for the treatment of autoimmune inflammation | 4SC DISCOVERY GMBH (DE) | 2013-01-15 | — | — | US | disclosed |
| EP-2414354-B1 | Hydroxy-methyl isoxazole derivatives as gaba a modulators | HOFFMANN LA ROCHE (CH) | 2012-12-12 | — | — | EP | disclosed |
| US-8269008-B2 | Oxazolopyridine and isoxazolopyridine derivatives for use in the treatment of HIF-mediated conditions | FIBROGEN, INC. (US) | 2012-09-18 | — | — | US | disclosed |
| WO-2012101263-A1 | IL17 AND IFN-GAMMA INHIBITION FOR THE TREATMENT OF AUTOIMMUNE INFLAMMATION | 4SC DISCOVERY GMBH (DE) | 2012-08-02 | — | — | WO | disclosed |
| US-20100303928-A1 | ISOXAZOLOPYRIDINE DERIVATIVES FOR USE IN THE TREATMENT OF HIF-MEDIATED CONDITIONS | FIBROGEN, INC. (US) | 2010-12-02 | — | — | US | disclosed |
| WO-2010112475-A1 | HYDROXY-METHYL ISOXAZOLE DERIVATIVES AS GABA A MODULATORS | F. HOFFMANN-LA ROCHE AG (CH) | 2010-10-07 | — | — | WO | disclosed |
| US-20100256127-A1 | SUBSTITUTED ISOXAZOLES | ROCHE PALO ALTO LLC | 2010-10-07 | — | — | US | disclosed |
| EP-2227475-A1 | ISOXAZOLOPYRIDINE DERIVATIVES FOR USE IN THE TREATMENT OF HIF-MEDIATED CONDITIONS | Fibrogen, Inc. (US) | 2010-09-15 | — | — | EP | disclosed |
| WO-2010025035-A1 | PROCESS FOR PREPARING ISOXAZOLE COMPOUNDS | DOW GLOBAL TECHNOLOGIES INC. (US) | 2010-03-04 | — | — | WO | disclosed |
| US-20100048910-A1 | PROCESS FOR PREPARING ISOXAZOLE COMPOUNDS | ANGUS CHEMICAL COMPANY | 2010-02-25 | — | — | US | disclosed |
| US-7612069-B2 | Acyl guanidines as beta-secretase inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2009-11-03 | — | — | US | disclosed |
| WO-2009073669-A1 | ISOXAZOLOPYRIDINE DERIVATIVES FOR USE IN THE TREATMENT OF HIF-MEDIATED CONDITIONS | FIBROGEN, INC. (US) | 2009-06-11 | — | — | WO | disclosed |
| US-7273882-B2 | Aminoacetamide acyl guanidines as β-secretase inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2007-09-25 | — | — | US | disclosed |
| US-20070015754-A1 | Acyl guanidines as beta-secretase inhibitors | BRISTOL-MYERS SQUIBB COMPANY | 2007-01-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100256127-A1 | SUBSTITUTED ISOXAZOLES | GABRA5, GABRA1, GABRA3 | TSHR 557/4885POLB 4593/4885ALOX15 1725/4885 |
| US-20100303928-A1 | ISOXAZOLOPYRIDINE DERIVATIVES FOR USE IN THE TREATMENT OF HIF-MEDIATED CONDITIONS | HIF1AN, HIF1A, EGLN2 | TSHR 3158/4885POLB 1984/4885ALOX15 2423/4885 |
| US-20100048910-A1 | PROCESS FOR PREPARING ISOXAZOLE COMPOUNDS | CYP11B2, CYP11B1, CYP3A7 | TSHR 3112/4885POLB 794/4885ALOX15 1072/4885 |
| US-20070015754-A1 | Acyl guanidines as beta-secretase inhibitors | BACE1, APP, BACE2 | TSHR 3913/4885POLB 2790/4885ALOX15 3140/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.